The relationship between uric acid levels and Huntington's disease progression
Identifieur interne : 000343 ( Istex/Corpus ); précédent : 000342; suivant : 000344The relationship between uric acid levels and Huntington's disease progression
Auteurs : Peggy Auinger ; Karl Kieburtz ; Michael McdermottSource :
- Movement Disorders [ 0885-3185 ] ; 2010-01-30.
English descriptors
- KwdEn :
Abstract
Uric acid (UA) may be associated with the progression of Parkinson's disease and related neurodegenerative conditions; however, its association with Huntington's disease (HD) progression has not been explored. A secondary analysis of 347 subjects from the CARE‐HD clinical trial was performed to examine the relationship between baseline UA levels and the level of functional decline in HD. Outcomes included change in scores at 30 months for the Unified Huntington's Disease Rating Scale components. There was less worsening of total functional capacity over time with increasing baseline UA levels (adjusted mean worsening in scores: 3.17, 2.99, 2.95, 2.28, 2.21, from lowest to highest UA quintile, P = 0.03). These data suggest a possible association between higher UA levels and slower HD progression, particularly as measured by total functional capacity. If confirmed, UA could be an important predictor and potentially modifiable factor affecting the rate of HD progression. © 2009 Movement Disorder Society
Url:
DOI: 10.1002/mds.22907
Links to Exploration step
ISTEX:600962A0251CB74FF3391D05035604C8104C4E44Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The relationship between uric acid levels and Huntington's disease progression</title><author><name sortKey="Auinger, Peggy" sort="Auinger, Peggy" uniqKey="Auinger P" first="Peggy" last="Auinger">Peggy Auinger</name><affiliation><mods:affiliation>Departments of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York</mods:affiliation></affiliation></author><author><name sortKey="Kieburtz, Karl" sort="Kieburtz, Karl" uniqKey="Kieburtz K" first="Karl" last="Kieburtz">Karl Kieburtz</name><affiliation><mods:affiliation>Departments of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York</mods:affiliation></affiliation></author><author><name sortKey="Mcdermott, Michael P" sort="Mcdermott, Michael P" uniqKey="Mcdermott M" first="Michael" last="Mcdermott">Michael Mcdermott</name><affiliation><mods:affiliation>Departments of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York</mods:affiliation></affiliation><affiliation><mods:affiliation>Departments of Biostatistics and Computational Biology, University of Rochester School of Medicine and Dentistry, Rochester, New York</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:600962A0251CB74FF3391D05035604C8104C4E44</idno><date when="2010" year="2010">2010</date><idno type="doi">10.1002/mds.22907</idno><idno type="url">https://api.istex.fr/document/600962A0251CB74FF3391D05035604C8104C4E44/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000343</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The relationship between uric acid levels and Huntington's disease progression</title><author><name sortKey="Auinger, Peggy" sort="Auinger, Peggy" uniqKey="Auinger P" first="Peggy" last="Auinger">Peggy Auinger</name><affiliation><mods:affiliation>Departments of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York</mods:affiliation></affiliation></author><author><name sortKey="Kieburtz, Karl" sort="Kieburtz, Karl" uniqKey="Kieburtz K" first="Karl" last="Kieburtz">Karl Kieburtz</name><affiliation><mods:affiliation>Departments of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York</mods:affiliation></affiliation></author><author><name sortKey="Mcdermott, Michael P" sort="Mcdermott, Michael P" uniqKey="Mcdermott M" first="Michael" last="Mcdermott">Michael Mcdermott</name><affiliation><mods:affiliation>Departments of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York</mods:affiliation></affiliation><affiliation><mods:affiliation>Departments of Biostatistics and Computational Biology, University of Rochester School of Medicine and Dentistry, Rochester, New York</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-01-30">2010-01-30</date><biblScope unit="volume">25</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="224">224</biblScope><biblScope unit="page" to="228">228</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">600962A0251CB74FF3391D05035604C8104C4E44</idno><idno type="DOI">10.1002/mds.22907</idno><idno type="ArticleID">MDS22907</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Huntington's disease</term><term>progression</term><term>uric acid</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Uric acid (UA) may be associated with the progression of Parkinson's disease and related neurodegenerative conditions; however, its association with Huntington's disease (HD) progression has not been explored. A secondary analysis of 347 subjects from the CARE‐HD clinical trial was performed to examine the relationship between baseline UA levels and the level of functional decline in HD. Outcomes included change in scores at 30 months for the Unified Huntington's Disease Rating Scale components. There was less worsening of total functional capacity over time with increasing baseline UA levels (adjusted mean worsening in scores: 3.17, 2.99, 2.95, 2.28, 2.21, from lowest to highest UA quintile, P = 0.03). These data suggest a possible association between higher UA levels and slower HD progression, particularly as measured by total functional capacity. If confirmed, UA could be an important predictor and potentially modifiable factor affecting the rate of HD progression. © 2009 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Peggy Auinger MS</name><affiliations><json:string>Departments of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York</json:string></affiliations></json:item><json:item><name>Karl Kieburtz MD</name><affiliations><json:string>Departments of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York</json:string></affiliations></json:item><json:item><name>Michael P. Mcdermott PhD</name><affiliations><json:string>Departments of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York</json:string><json:string>Departments of Biostatistics and Computational Biology, University of Rochester School of Medicine and Dentistry, Rochester, New York</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Huntington's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>uric acid</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>progression</value></json:item></subject><language><json:string>eng</json:string></language><abstract>Uric acid (UA) may be associated with the progression of Parkinson's disease and related neurodegenerative conditions; however, its association with Huntington's disease (HD) progression has not been explored. A secondary analysis of 347 subjects from the CARE‐HD clinical trial was performed to examine the relationship between baseline UA levels and the level of functional decline in HD. Outcomes included change in scores at 30 months for the Unified Huntington's Disease Rating Scale components. There was less worsening of total functional capacity over time with increasing baseline UA levels (adjusted mean worsening in scores: 3.17, 2.99, 2.95, 2.28, 2.21, from lowest to highest UA quintile, P = 0.03). These data suggest a possible association between higher UA levels and slower HD progression, particularly as measured by total functional capacity. If confirmed, UA could be an important predictor and potentially modifiable factor affecting the rate of HD progression. © 2009 Movement Disorder Society</abstract><qualityIndicators><score>6.812</score><pdfVersion>1.3</pdfVersion><pdfPageSize>612 x 810 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>3</keywordCount><abstractCharCount>1015</abstractCharCount><pdfWordCount>12171</pdfWordCount><pdfCharCount>80524</pdfCharCount><pdfPageCount>22</pdfPageCount><abstractWordCount>151</abstractWordCount></qualityIndicators><title>The relationship between uric acid levels and Huntington's disease progression</title><genre><json:string>article</json:string></genre><host><volume>25</volume><pages><total>5</total><last>228</last><first>224</first></pages><issn><json:string>0885-3185</json:string></issn><issue>2</issue><subject><json:item><value>Brief Report</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><eissn><json:string>1531-8257</json:string></eissn><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2010</publicationDate><copyrightDate>2010</copyrightDate><doi><json:string>10.1002/mds.22907</json:string></doi><id>600962A0251CB74FF3391D05035604C8104C4E44</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/600962A0251CB74FF3391D05035604C8104C4E44/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/600962A0251CB74FF3391D05035604C8104C4E44/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/600962A0251CB74FF3391D05035604C8104C4E44/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">The relationship between uric acid levels and Huntington's disease progression</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>WILEY</p></availability><date>2010</date></publicationStmt><notesStmt><note type="content">*Potential confilct of interest: None.</note><note>NIH</note><note>NINDS - No. #NS R01‐35284;</note><note>General Clinical Research Centers - No. RR00052; No. RR00645; No. RR00042; No. RR00044; No. RR01066; No. RR07122;</note><note>Astra‐Zeneca</note><note>Vitaline</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">The relationship between uric acid levels and Huntington's disease progression</title><author><persName><forename type="first">Peggy</forename><surname>Auinger</surname></persName><roleName type="degree">MS</roleName><note type="correspondence"><p>Correspondence: Department of Neurology, University of Rochester, 1351 Mt. Hope Ave., Rochester 14620, NY</p></note><affiliation>Departments of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York</affiliation></author><author><persName><forename type="first">Karl</forename><surname>Kieburtz</surname></persName><roleName type="degree">MD</roleName><affiliation>Departments of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York</affiliation></author><author><persName><forename type="first">Michael P.</forename><surname>Mcdermott</surname></persName><roleName type="degree">PhD</roleName><affiliation>Departments of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York</affiliation><affiliation>Departments of Biostatistics and Computational Biology, University of Rochester School of Medicine and Dentistry, Rochester, New York</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2010-01-30"></date><biblScope unit="volume">25</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="224">224</biblScope><biblScope unit="page" to="228">228</biblScope></imprint></monogr><idno type="istex">600962A0251CB74FF3391D05035604C8104C4E44</idno><idno type="DOI">10.1002/mds.22907</idno><idno type="ArticleID">MDS22907</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2010</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Uric acid (UA) may be associated with the progression of Parkinson's disease and related neurodegenerative conditions; however, its association with Huntington's disease (HD) progression has not been explored. A secondary analysis of 347 subjects from the CARE‐HD clinical trial was performed to examine the relationship between baseline UA levels and the level of functional decline in HD. Outcomes included change in scores at 30 months for the Unified Huntington's Disease Rating Scale components. There was less worsening of total functional capacity over time with increasing baseline UA levels (adjusted mean worsening in scores: 3.17, 2.99, 2.95, 2.28, 2.21, from lowest to highest UA quintile, P = 0.03). These data suggest a possible association between higher UA levels and slower HD progression, particularly as measured by total functional capacity. If confirmed, UA could be an important predictor and potentially modifiable factor affecting the rate of HD progression. © 2009 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Huntington's disease</term></item><item><term>uric acid</term></item><item><term>progression</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>article category</head><item><term>Brief Report</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2009-01-12">Received</change><change when="2009-10-30">Registration</change><change when="2010-01-30">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/600962A0251CB74FF3391D05035604C8104C4E44/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="20"><doi origin="wiley" registered="yes">10.1002/mds.v25:2</doi><numberingGroup><numbering type="journalVolume" number="25">25</numbering><numbering type="journalIssue">2</numbering></numberingGroup><coverDate startDate="2010-01-30">30 January 2010</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="120" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.22907</doi><idGroup><id type="unit" value="MDS22907"></id></idGroup><countGroup><count type="pageTotal" number="5"></count></countGroup><titleGroup><title type="articleCategory">Brief Report</title><title type="tocHeading1">Brief Reports</title></titleGroup><copyright ownership="thirdParty">Copyright © 2009 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2009-01-12"></event><event type="manuscriptRevised" date="2009-07-08"></event><event type="manuscriptAccepted" date="2009-10-30"></event><event type="firstOnline" date="2010-01-08"></event><event type="publishedOnlineFinalForm" date="2010-02-24"></event><event type="publishedOnlineAcceptedOrEarlyUnpaginated" date="2010-01-08"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.5.2 mode:FullText" date="2011-07-19"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">224</numbering><numbering type="pageLast">228</numbering></numberingGroup><correspondenceTo>Department of Neurology, University of Rochester, 1351 Mt. Hope Ave., Rochester 14620, NY</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS22907.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="0"></count><count type="tableTotal" number="2"></count><count type="referenceTotal" number="18"></count><count type="wordTotal" number="3921"></count></countGroup><titleGroup><title type="main" xml:lang="en">The relationship between uric acid levels and Huntington's disease progression<link href="#fn1"></link></title><title type="short" xml:lang="en">Uric Acid and HD Progression</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Peggy</givenNames><familyName>Auinger</familyName><degrees>MS</degrees></personName><contactDetails><email>Peggy.Auinger@ctcc.rochester.edu</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Karl</givenNames><familyName>Kieburtz</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1 #af2"><personName><givenNames>Michael P.</givenNames><familyName>Mcdermott</familyName><degrees>PhD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Departments of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="US" type="organization"><unparsedAffiliation>Departments of Biostatistics and Computational Biology, University of Rochester School of Medicine and Dentistry, Rochester, New York</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Huntington's disease</keyword><keyword xml:id="kwd2">uric acid</keyword><keyword xml:id="kwd3">progression</keyword></keywordGroup><fundingInfo><fundingAgency>NIH</fundingAgency></fundingInfo><fundingInfo><fundingAgency>NINDS</fundingAgency><fundingNumber>#NS R01‐35284</fundingNumber></fundingInfo><fundingInfo><fundingAgency>General Clinical Research Centers</fundingAgency><fundingNumber>RR00052</fundingNumber><fundingNumber>RR00645</fundingNumber><fundingNumber>RR00042</fundingNumber><fundingNumber>RR00044</fundingNumber><fundingNumber>RR01066</fundingNumber><fundingNumber>RR07122</fundingNumber></fundingInfo><fundingInfo><fundingAgency>Astra‐Zeneca</fundingAgency></fundingInfo><fundingInfo><fundingAgency>Vitaline</fundingAgency></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Uric acid (UA) may be associated with the progression of Parkinson's disease and related neurodegenerative conditions; however, its association with Huntington's disease (HD) progression has not been explored. A secondary analysis of 347 subjects from the CARE‐HD clinical trial was performed to examine the relationship between baseline UA levels and the level of functional decline in HD. Outcomes included change in scores at 30 months for the Unified Huntington's Disease Rating Scale components. There was less worsening of total functional capacity over time with increasing baseline UA levels (adjusted mean worsening in scores: 3.17, 2.99, 2.95, 2.28, 2.21, from lowest to highest UA quintile, <i>P</i> = 0.03). These data suggest a possible association between higher UA levels and slower HD progression, particularly as measured by total functional capacity. If confirmed, UA could be an important predictor and potentially modifiable factor affecting the rate of HD progression. © 2009 Movement Disorder Society</p></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p>Potential confilct of interest: None.</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>The relationship between uric acid levels and Huntington's disease progression</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Uric Acid and HD Progression</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>The relationship between uric acid levels and Huntington's disease progression</title></titleInfo><name type="personal"><namePart type="given">Peggy</namePart><namePart type="family">Auinger</namePart><namePart type="termsOfAddress">MS</namePart><affiliation>Departments of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York</affiliation><description>Correspondence: Department of Neurology, University of Rochester, 1351 Mt. Hope Ave., Rochester 14620, NY</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Karl</namePart><namePart type="family">Kieburtz</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Departments of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Michael P.</namePart><namePart type="family">Mcdermott</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Departments of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, New York</affiliation><affiliation>Departments of Biostatistics and Computational Biology, University of Rochester School of Medicine and Dentistry, Rochester, New York</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2010-01-30</dateIssued><dateCaptured encoding="w3cdtf">2009-01-12</dateCaptured><dateValid encoding="w3cdtf">2009-10-30</dateValid><copyrightDate encoding="w3cdtf">2010</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="tables">2</extent><extent unit="references">18</extent><extent unit="words">3921</extent></physicalDescription><abstract lang="en">Uric acid (UA) may be associated with the progression of Parkinson's disease and related neurodegenerative conditions; however, its association with Huntington's disease (HD) progression has not been explored. A secondary analysis of 347 subjects from the CARE‐HD clinical trial was performed to examine the relationship between baseline UA levels and the level of functional decline in HD. Outcomes included change in scores at 30 months for the Unified Huntington's Disease Rating Scale components. There was less worsening of total functional capacity over time with increasing baseline UA levels (adjusted mean worsening in scores: 3.17, 2.99, 2.95, 2.28, 2.21, from lowest to highest UA quintile, P = 0.03). These data suggest a possible association between higher UA levels and slower HD progression, particularly as measured by total functional capacity. If confirmed, UA could be an important predictor and potentially modifiable factor affecting the rate of HD progression. © 2009 Movement Disorder Society</abstract><note type="content">*Potential confilct of interest: None.</note><note type="funding">NIH</note><note type="funding">NINDS - No. #NS R01‐35284; </note><note type="funding">General Clinical Research Centers - No. RR00052; No. RR00645; No. RR00042; No. RR00044; No. RR01066; No. RR07122; </note><note type="funding">Astra‐Zeneca</note><note type="funding">Vitaline</note><subject lang="en"><genre>Keywords</genre><topic>Huntington's disease</topic><topic>uric acid</topic><topic>progression</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Brief Report</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>25</number></detail><detail type="issue"><caption>no.</caption><number>2</number></detail><extent unit="pages"><start>224</start><end>228</end><total>5</total></extent></part></relatedItem><identifier type="istex">600962A0251CB74FF3391D05035604C8104C4E44</identifier><identifier type="DOI">10.1002/mds.22907</identifier><identifier type="ArticleID">MDS22907</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2009 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/JankovicV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000343 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000343 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= JankovicV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:600962A0251CB74FF3391D05035604C8104C4E44
|texte= The relationship between uric acid levels and Huntington's disease progression
}}
| This area was generated with Dilib version V0.6.19. |  |